Picture of Trevi Therapeutics logo

TRVI — Trevi Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Trevi Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

* Trevi Therapeutics Inc  TRVI.OQ  reported a quarterly
adjusted
loss of 13 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -8 cents.  The mean expectation of nine analysts for the
quarter was for a loss of 12 cents per share. Wall Street
expected results to range from -13 cents to -9 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Trevi Therapeutics Inc's reported EPS for the quarter was
a loss
of 13 cents​.
    * The company reported a quarterly loss of $13.24 million.
    * Trevi Therapeutics Inc shares had fallen by 9.6% this
quarter and gained 125.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 8.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Trevi
Therapeutics Inc is $8.00 
This summary was machine generated from LSEG data November 7 at
04:57 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.12          -0.13          Missed
 Jun. 30 2024      -0.11          -0.12          Missed
 Mar. 31 2024      -0.09          -0.11          Missed
 Dec. 31 2023      -0.09          -0.08          Beat

Recent news on Trevi Therapeutics

See all news